8.06
0.49%
-0.04
After Hours:
8.06
Theravance Biopharma Inc stock is traded at $8.06, with a volume of 240.15K.
It is down -0.49% in the last 24 hours and down -2.30% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$8.10
Open:
$8.07
24h Volume:
240.15K
Relative Volume:
0.66
Market Cap:
$393.93M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
0.7095
EPS:
11.36
Net Cash Flow:
$-9.60M
1W Performance:
+1.51%
1M Performance:
-2.30%
6M Performance:
-10.14%
1Y Performance:
-6.60%
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-23-22 | Initiated | SVB Leerink | Outperform |
Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jul-07-20 | Initiated | JP Morgan | Overweight |
Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
May-13-20 | Initiated | Cowen | Outperform |
Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
Oct-29-19 | Initiated | H.C. Wainwright | Buy |
Mar-29-18 | Resumed | Piper Jaffray | Overweight |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
May-11-17 | Reiterated | Needham | Buy |
Dec-21-16 | Initiated | Needham | Buy |
Nov-03-16 | Initiated | Piper Jaffray | Overweight |
Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jun-20-16 | Initiated | Guggenheim | Buy |
Jun-20-16 | Reiterated | Leerink Partners | Outperform |
May-12-16 | Initiated | Leerink Partners | Outperform |
May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Rhumbline Advisers Sells 15,095 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
An Analysis of Theravance Biopharma Inc (TBPH)’s Potential Price Growth - Knox Daily
Theravance Biopharma settles patent litigation with Qilu Pharmaceutical - Investing.com
Baupost Group LLC MA Decreases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains Buy rating on Theravance Biopharma shares By Investing.com - Investing.com Canada
Theravance Biopharma (NASDAQ:TBPH) Receives Buy Rating from HC Wainwright - MarketBeat
Unveiling 4 Analyst Insights On Theravance Biopharma - Benzinga
How To Trade (TBPH) - Stock Traders Daily
Leerink Partners gives a Market perform recommendation for Theravance Biopharma Inc (TBPH) - Knox Daily
Seth Klarman's Complete Exit from Theravance Biopharma Inc - Yahoo Finance
Theravance Biopharma Outlines Growth Strategy at Investment Conference - TipRanks
Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation - Yahoo Finance
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Theravance Biopharma Inc (TBPH) receives a Market perform rating from Leerink Partners - Knox Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of “Hold” by Analysts - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Target Price from Analysts - MarketBeat
Q3 2024 EPS Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH) Reduced by Analyst - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 50-Day Moving Average of $8.90 - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q4 2025 Earnings of $0.41 Per Share, Zacks Research Forecasts - Defense World
Zacks Research Brokers Increase Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizentribune
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Below Fifty Day Moving Average of $8.90 - Defense World
Theravance Biopharma to Participate in an Upcoming Investor Conference - StockTitan
TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024 - MSN
Leerink Partners Downgrades Theravance Biopharma Inc (TBPH) to a Market perform from an Outperform - Knox Daily
TBPH (Theravance Biopharma) 14-Day RSI : 42.38 (As of Aug. 20, 2024) - GuruFocus.com
TBPH (Theravance Biopharma) Short-Term Debt & Capital Lease Obligation : $4.22 Mil (As of Jun. 2024) - GuruFocus.com
TBPH (Theravance Biopharma) 3-Year Revenue Growth Rate : -3.40% (As of Jun. 2024) - GuruFocus.com
TBPH (Theravance Biopharma) LT-Debt-to-Total-Asset : 0.12 (As of Jun. 2024) - GuruFocus.com
TBPH (Theravance Biopharma) Free Cash Flow : $-9.60 Mil (TTM As of Jun. 2024) - GuruFocus.com
SG Americas Securities LLC Sells 47,178 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Price T Rowe Associates Inc. MD Purchases 3,532 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc [TBPH] Stock bought by Insider Samaha Eli for $7.8 million - Knox Daily
Seth Klarman's Strategic Reduction in Theravance Biopharma Inc - Yahoo Finance
Klarman's Baupost adds WilScot, Capri, exits Altice USA, among others (NASDAQ:TBPH) - Seeking Alpha
Vanguard Group Inc. Has $24.09 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma Second Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Vanguard Group Inc. Decreases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Major Shareholder Eli Samaha Buys 999,800 Shares of Stock - Defense World
Need To Know: Analysts Just Made A Substantial Cut To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Estimates - Yahoo Finance
StockNews.com Downgrades Theravance Biopharma (NASDAQ:TBPH) to Hold - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to Hold at StockNews.com - Defense World
Eli Samaha buys $7.8 million worth of Theravance Biopharma stock - Investing.com India
Eli Samaha buys $7.8 million worth of Theravance Biopharma stock By Investing.com - Investing.com Canada
Eli Samaha buys $7.8 million worth of Theravance Biopharma stock - Investing.com
Eli Samaha buys $7.8 million worth of Theravance Biopharma stock By Investing.com - Investing.com Australia
Theravance Biopharma (FRA:0TB) Owner Earnings per Share (TT - GuruFocus.com
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):